Preparation method of beta2-microglobulin and polyclonal antibody thereof
By extracting β2-microglobulin from urine and using polyclonal antibody technology, the problem of high cost of preparation of β2-microglobulin is solved, and high-purity and low-cost antibody preparation is achieved, with a wide range of clinical and in vitro diagnostic applications. value.
Patent Information
- Application Number
- CN202411218875.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-11-22
AI Technical Summary
The existing β2-microglobulin preparation methods are costly, resulting in an increase in clinical testing costs.
High purity β2-MG polyclonal antibody was prepared using multiple immune goats, coupled with 4% highly crosslinked agarose preactivated by N-hydroxysuccinimide, An antigen affinity purification column was prepared to obtain high-purity β2-MG polyclonal antibody.
It reduces the cost of β2-microglobulin preparation, improves the purity and specificity of the antibody, and expands the application value of clinical diagnosis and in vitro detection.
Smart Images

Figure CN118994356A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of bioengineering technology, and in particular to a method for preparing beta 2-microglobulin and a polyclonal antibody thereof. Background Art
[0002] β2-microglobulin (β2-MG) is a single-chain polypeptide small molecule globulin composed of 99 amino acids. It contains disulfide bonds in the chain, which is similar to the structure of the stable region of immunoglobulin. The molecular weight is 11.8KDa. It is mainly produced by lymphocytes, platelets, and polymorphonuclear leukocytes. It is also the β chain (light chain) part of the human leukocyte antigen (HLA) on the cell surface. β2-MG is widely present in plasma, urine, cerebrospinal fluid, saliva, and colostrum. The amount of β2-microglobulin synthesized in the normal human body and its release on the cell membrane are extremely stable. After β2-microglobulin is filtered from the glomerulus, 99.9% is absorbed in the proximal renal tubules and decomposed and destroyed in the renal tubular epithelial cells. Therefore, under normal circumstances, the excretion of β2-MG is extremely trace. The content of β2-MG in normal human blood is generally between 0.8-2mg / L, and the content of β2-MG in urine is generally less than 0.2mg / L.
[0003] β2-microglobulin (β2-MG) is metabolized by the kidneys. Abnormal metabolism indicates problems with kidney function. When the glomeruli are damaged or the filtration load is overloaded, the amount of β2-MG excreted in the urine increases. When the glomerular filtration rate (GFR) drops to 50% of normal, blood β2-MG will increase by 1 time, while blood creatinine will only start to increase when GFR drops to 70% of normal. Therefore, measuring blood β2-MG can reflect glomerular filtration function earlier, and it is earlier and more sensitive than the increase in blood creatinine concentration. In clinical practice, the measurement of β2-MG can be used as an indicator of kidney function. Because the lymphatic system is the main site of β2-MG synthesis, when lymphocytes are overactive, it will also cause abnormal blood β2-MG content, such as certain autoimmune diseases, bacterial and viral infections (HIV, CMV, EBV), tumors such as myeloma lymphoma, and transplant rejection.
[0004] At present, the methods used in clinical practice to detect β2-MG content include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunotransmission turbidimetry (PETIA), immunoscattering turbidimetry (PEINA), chemiluminescence (CL) and colloidal gold method (RT), all of which require specific and high-performance antibodies. Summary of the invention
[0005] The object of the present invention is to provide a method for preparing β2-microglobulin and its polyclonal antibody, aiming to solve the problem of high cost of existing β2-microglobulin preparation.
[0006] To achieve the above object, the present invention provides a method for preparing β2-microglobulin and its polyclonal antibody, comprising the following steps:
[0007] β2-microglobulin solution was extracted from urine after pretreatment;
[0008] Using the β2-microglobulin as an immunogen to immunize goats multiple times, and collecting serum for qualified testing to obtain qualified serum;
[0009] The β2-microglobulin is coupled to 4% highly cross-linked agarose pre-activated by N-hydroxysuccinimide to obtain an antigen affinity purification column;
[0010] High-purity β2-MG polyclonal antibodies are prepared based on the qualified serum and the antigen affinity purification column.
[0011] Among them, in "extracting β2-microglobulin after pretreatment of urine", it includes:
[0012] The urine is filtered, concentrated and dialyzed to obtain a protein solution A;
[0013] The protein solution A is added to the equilibrium column, and then eluted, collected and concentrated to obtain β2-MG;
[0014] Treating and testing the β2-MG to obtain protein solution B;
[0015] Putting the protein solution B into a dialysis bag for dialysis to obtain protein solution C;
[0016] The protein solution C is subjected to washing, elution and detection to obtain a β2-microglobulin solution.
[0017] Among them, in “using the β2-microglobulin as an immunogen to immunize goats multiple times, and collecting serum for qualified testing to obtain qualified serum”, the qualified serum is the serum screened by the two-way agar diffusion experiment.
[0018] Among them, in “coupling the β2-microglobulin with 4% highly cross-linked agarose pre-activated by N-hydroxysuccinimide to obtain an antigen affinity purification column”, it includes:
[0019] The 4% highly cross-linked agarose pre-activated with N-hydroxysuccinimide was washed and diluted to obtain a diluted filler;
[0020] dialyzing the β2-microglobulin to obtain an antigen solution;
[0021] Mixing the diluted filler and the antigen solution to obtain a mixed solution A;
[0022] The mixed solution A is washed to obtain an antigen affinity purification column.
[0023] Among them, "preparing high-purity β2-MG polyclonal antibodies based on the qualified serum and the antigen affinity purification column" includes:
[0024] Centrifuging, filtering and mixing the qualified serum to obtain a mixed solution B;
[0025] Using a buffer to balance the antigen affinity purification column, and loading the mixed solution B, followed by washing and elution to obtain an eluate;
[0026] Adding (NH4)2SO4 to the eluate, stirring, standing and centrifuging, removing the supernatant, adding a buffer solution for re-dissolution, and obtaining a re-solution solution;
[0027] The reconstituted solution is dialyzed and centrifuged, and then 0.01-0.5% Proclin300 is added to obtain highly pure β2-MG polyclonal antibodies.
[0028] The method for preparing a β2-microglobulin and a polyclonal antibody thereof of the present invention comprises the following steps:
[0029] The β2-microglobulin solution is extracted from urine after pretreatment; the β2-microglobulin is used as an immunogen to immunize goats multiple times, and serum is collected for qualified detection to obtain qualified serum; the β2-microglobulin is coupled with 4% highly cross-linked agarose pre-activated by N-hydroxysuccinimide to obtain an antigen affinity purification column; based on the qualified serum and the antigen affinity purification column, a high-purity β2-MG polyclonal antibody is obtained. The β2-MG prepared by the present invention has low cost, simple operation, and high purity. It can not only be used as an effective immunogen and can be used for the preparation of β2-MG polyclonal antibodies; it can also be used as a calibration material for a detection kit. The antibody has good specificity (high analytical sensitivity), a wide linear range, and a low detection limit, and has potential and wide application value in clinical diagnosis and in vitro diagnosis, thereby solving the problem of high cost of existing β2-microglobulin preparation. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0031] Figure 1 This is the purity test chart of high-purity β2-MG
[0032] Figure 2 This is a purity test chart of high-purity β2-MG polyclonal antibody.
[0033] Figure 3 It is a working curve graph with the concentration of the calibration substance as the independent variable and the absorbance as the dependent variable.
[0034] Figure 4 It is a linear range graph.
[0035] Figure 5 The present invention provides a flow chart of a method for preparing β2-microglobulin and its polyclonal antibody.
[0036] Figure 6 This is a flowchart of step S1.
[0037] Figure 7 This is a flowchart of step S3.
[0038] Figure 8 This is a flowchart of step S4. DETAILED DESCRIPTION
[0039] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.
[0040] See also Figures 1 to 8 The present invention provides a method for preparing β2-microglobulin and its polyclonal antibody, comprising the following steps:
[0041] S1 extracts β2-microglobulin solution after pretreatment of urine;
[0042] S11 filters, removes impurities, concentrates and dialyzes the urine to obtain a protein solution A;
[0043] The urine is human urine.
[0044] Specifically, 100 L of urine was pretreated, filtered to remove impurities, concentrated using a concentration device, the volume was controlled between 5-10% of the original volume, and dialyzed using a dialysis bag for 48 hours, during which the liquid was changed twice, the dialysate was Tris-HCl, and protein solution A was obtained.
[0045] S12: adding the protein solution A to the equilibrium column, eluting, collecting and concentrating to obtain β2-MG;
[0046] Specifically, the column is balanced with anion exchange column balance solution until the conductivity deviation between the effluent and the anion exchange column balance solution is within ±15%, the protein solution A is added to the balanced column, the impurities are washed with 2-3 column volumes of anion exchange column balance solution, and then eluted with 3-5 column volumes of anion exchange column eluent, and the eluent is collected. The eluent is concentrated to a total protein concentration of 50-80 mg / ml to obtain crude β2-MG.
[0047] S13 processes and detects the β2-MG to obtain a protein solution B;
[0048] Specifically, the column is balanced with 1-1.5 times column volume of molecular sieve S-300 buffer, the nucleic acid protein detector is turned on and zeroed, the β2-MG intermediate is loaded, and when the concentrate just enters the column, the molecular sieve S-300 buffer is slowly added for elution. When the detector shows an obvious rise, the penetration liquid of different penetration peaks is collected in different divisions, and the collected penetration liquid is tested for purity (SDS-PAGE), and the protein solution B with a purity of ≥80% and a protein band that meets the standard (11.8KD) is selected.
[0049] S14: placing the protein solution B into a dialysis bag for dialysis to obtain protein solution C;
[0050] Specifically, protein solution B is transferred to a dialysis bag (6-8KD), concentrated with sucrose, and the dialysis bag is covered with sucrose. After concentration, the volume is controlled to be 10-20% of the volume of protein solution B. The concentrate is dialyzed with DEAE column buffer, and the buffer is changed 3-4 times to obtain protein solution C.
[0051] S15 washes, elutes and detects the protein solution C to obtain a β2-microglobulin solution.
[0052] Specifically, DEAE ion exchange column was balanced with DEAE ion exchange column buffer, protein solution C was loaded, impurities were washed with DEAE column buffer, and finally eluted with DEAE ion exchange column eluent. The protein detector began to receive when the protein began to rise, and the tube was changed in time when a new peak appeared. The collected penetration solution was tested for purity (SDS-PAGE). The penetration solution with a purity of ≥95% was a natural high-purity β2-microglobulin solution. Purity test as follows Figure 1 .
[0053] S2 uses the β2-microglobulin as an immunogen to immunize goats multiple times, and collects serum for qualified testing to obtain qualified serum;
[0054] The qualified serum is the serum screened by the two-way agar diffusion experiment.
[0055] Specifically, the β2-microglobulin prepared in step (1) is used as an immunogen to immunize goats multiple times, serum is collected, and the serum is tested for qualification. The qualified serum is the serum screened by a two-way agar diffusion experiment.
[0056] S3 coupling the β2-microglobulin with 4% highly cross-linked agarose pre-activated by N-hydroxysuccinimide to obtain an antigen affinity purification column;
[0057] S31 was used to wash and dilute 4% highly cross-linked agarose pre-activated with N-hydroxysuccinimide to obtain diluted filler;
[0058] Specifically, a certain volume of 4% highly cross-linked agarose (NHS-activated Bestarose 4FF filler) pre-activated with N-hydroxysuccinimide is taken and washed with pre-cooled solution A (1 mM HCl) for at least 30 min, 1 mL of filler is washed with 15-30 mL of solution A, and after washing, the filler is diluted with solution A (about 0.5 mL of solution A is used for 1 mL of filler) to obtain diluted filler.
[0059] S32 dialyze the β2-microglobulin to obtain an antigen solution;
[0060] Specifically, the high-purity antigen solution B (composed of 0.05-0.2M NaHCO3 and 0.2-1M NaCl, pH 7-9) was dialyzed, and 1 mL of filler was coupled with 3-10 mg of antigen to obtain an antigen solution.
[0061] S33: mixing the diluted filler and the antigen solution to obtain a mixed solution A;
[0062] Specifically, the diluted filler and the antigen solution were mixed in equal volumes, mixed at room temperature for 4 hours and then incubated at 4°C overnight.
[0063] S34: washing the mixed solution A to obtain an antigen affinity purification column.
[0064] Specifically, the coupled filler is loaded into the column, the coupled supernatant is discharged, and a blocking solution (0.05-0.2M Tris-HCl, pH 7-9) is added, mixed, and blocked at room temperature for 4 hours. The blocking solution is discharged, and the cleaning solution 1 (0.05-0.2M Tris-HCl and 0.2-1M NaCl, pH 8-9) and the cleaning solution 2 (0.1-0.2M acetate buffer and 0.1-1M NaCl, pH 3-4) are used to wash alternately 3-6 times, and each time a solution of 3-5 times the volume of the gel is used for washing. Finally, the PBS buffer solution 1 (pH 7-8) is used for washing and standby.
[0065] S4 prepares high-purity β2-MG polyclonal antibodies based on the qualified serum and the antigen affinity purification column.
[0066] S41 centrifuges, filters and mixes the qualified serum to obtain a mixed solution B;
[0067] Specifically, the collected antiserum was centrifuged at 9000 rpm at 4°C for 20 min, the precipitate was removed by filtration, and the antiserum was mixed with an equal volume of PBS buffer 1 (pH 7-8) to obtain a mixed solution B.
[0068] S42: balancing the antigen affinity purification column with a buffer, and loading the mixed solution B, washing and eluting the mixed solution to obtain an eluate;
[0069] Specifically, 5 column volumes of PBS buffer 1 (pH 7-8) were used to balance the antigen affinity column, and the sample was loaded according to the volume of 1-5 mL of antiserum corresponding to 1 ml of filler, and the loading was repeated twice. After the column was completed, the impurities were washed with 5 column volumes of PBS buffer 1 (pH 7-8). Finally, the elution buffer was used for elution, and the washing liquid of the peak was collected (detected by a protein detector), and Tris-HCl (pH 8-9) was used to adjust the pH of the eluate to keep it neutral. The eluate was the β2-MG polyclonal antibody.
[0070] S43 adding (NH4)2SO4 to the eluate, stirring, standing and centrifuging, removing the supernatant, adding a buffer solution for redissolution, and obtaining a redissolution;
[0071] Specifically, (NH4)2SO4 is added to the eluent to make its saturation 40%-60%, and stirred while adding, and stirred for 0.5h after all the solids are dissolved, and then allowed to stand for 4h. After centrifugation at 9000rpm at 4℃ for 20min, the supernatant is removed, and the precipitate is re-dissolved with PBS buffer 1 (pH7-8), and the total protein concentration of the re-solution is controlled at 10-30mg / mL to obtain a re-solution.
[0072] S44: dialyzing and centrifuging the reconstituted solution, and then adding 0.01-0.5% Proclin300 to obtain a highly pure β2-MG polyclonal antibody.
[0073] Specifically, the complex solution is loaded into a dialysis bag (molecular weight cutoff 7-14KDa), the dialysis clamp is clamped, and then the dialysis bag is immersed in PBS buffer for 48 hours, and the buffer is changed every 6-10 hours. After centrifugation, the protein solution is filtered through a 0.22μm filter membrane, and 0.01-0.5% Proclin300 is added to obtain a highly pure goat anti-human β2-MG polyclonal antibody. Purity test as follows Figure 2 .
[0074] β2-MG polyclonal antibody validation:
[0075] A β2-MG immunoturbidimetric kit is prepared to test the calibration value, wherein the reagent R1 includes buffer 1 (e.g., phosphate, citrate), a surfactant (e.g., Triton X100), a stabilizer (e.g., NaCl), a chelating agent (e.g., EDTA), a sensitizer (e.g., PEG6000) and a preservative (e.g., NaN3).
[0076] Reagent R2: Dilute the above-mentioned goat anti-human β2-MG polyclonal antibody and the commercial goat anti-human β2-MG polyclonal antibody purchased from manufacturer A to the same concentration of 10-20 mg / mL with PBS buffer 1 (pH 7-8); dilute latex microspheres (carboxylated polystyrene latex, purchased from Wuxi Ninebot Biotechnology Co., Ltd., particle size 90 nm) to 5% (solid content) with purified water, then add 5-10% (EDC / latex microsphere mass ratio) of EDC, stir the reaction at 25-30°C for 30 minutes, and then add the diluted The antibody (1 mL of latex microspheres corresponds to 8-12 mg of antibody) is stirred for reaction at 25-30°C for 90-150 min, a termination reaction solution is added to terminate the reaction, the supernatant is removed by centrifugation, and a buffer 2 composed of a buffer (e.g., phosphate, citrate), a surfactant (e.g., TritonX100), a stabilizer (e.g., NaCl), a chelating agent (e.g., EDTA), a protective agent (e.g., BSA) and a preservative (e.g., NaN3) is added, and R2 reagent is obtained after ultrasonication for 60-150S.
[0077] Calibrators: A buffer consisting of buffer 3 (e.g., phosphate, citrate), stabilizers (e.g., NaCl), chelating agents (e.g., EDTA) and preservatives (e.g., NaN3) was added to different volumes of natural human β2-MG protein to prepare a set of calibrators with final concentrations of 18, 9, 4.5, 2.25, 1.125 and 0 mg / L (purified water was used as a control), and a high-value test product of 27 mg / L was also prepared.
[0078] Kit performance test: Control kit, the antibody used in reagent 2 is the commercial sheep anti-human polyclonal antibody of manufacturer A, and the other parameters are the same, and the test parameters are: main wavelength 600nm, sub-wavelength none, R1:R2:S=200:50:3. Test instrument: Hitachi 3500.
[0079] (1) Linear range verification: Use the kit of the present invention and the control kit to measure each calibrator and a high-value test product. Use the concentration of the calibrator as the independent variable and the absorbance as the dependent variable to obtain a working curve. Figure 3 As shown in the results, it can be seen that the detection range of the kit of the present invention is 0-18 mg / mL, and the linear correlation coefficient can reach 0.9999. Figure 4It can be seen that the kit of the present invention has a wider linear range, which is more conducive to the direct detection of high-concentration pathological samples without the need for sample dilution, thereby simplifying the operation.
[0080] (2) Antibody specificity (analytical sensitivity) verification: The test kit of the present invention and the control kit were used to repeatedly measure the sample of (3.0±0.2) mg / L three times, and the absorbance A generated by the reagent under the specified parameters was recorded, and the absorbance difference (ΔA) of 3.0 mg / L was converted according to formula (1), as shown in Table 1. It can be seen from the data in the table that when testing the sample of 3.0 mg / L, the kit of the present invention has a higher analytical sensitivity, that is, a better specificity.
[0081]
[0082] (3) Detection limit verification: The blank sample was repeatedly measured 20 times using the kit of the present invention and the control kit, and the mean value (M) and standard deviation (SD) were calculated. The detection limit = M + 2SD, see Table 2. As can be seen from the data in the table, the kit of the present invention has a lower detection limit, that is, higher sensitivity.
[0083]
[0084]
[0085] Table 1
[0086] Kit of the present invention Control Kit Test value 1 0 0 Test value 2 0 0 Test value 3 0 0.02 Test value 4 0 0 Test value 5 0 0 Test value 6 0 0.01 Test value 7 0 0 Test value 8 0.01 0 Test value 9 0 0.01 Test value 10 0 0 Test value 11 0 0 Test value 12 0 0 Test value 13 0 0.02 Test value 14 0 0 Test value 15 0 0 Test value 16 0.02 0 Test value 17 0 0.03 Test value 18 0 0 Test value 19 0 0 Test value 20 0 0 Average value M 0.0015 0.0045 Standard Deviation 0.0049 0.0089 Detection limit 0.0113 0.0222
[0087] Table 2
[0088] Beneficial effects:
[0089] (1) The present invention extracts β2-microglobulin from human urine, filters the urine, concentrates it and replaces the liquid, and then purifies it through an anion exchange column to obtain crude β2-MG, which is then purified through molecular sieve S-300 to obtain β2-microglobulin with a purity of ≥80%, and then concentrated and purified through anion exchange to obtain natural β2-microglobulin with a purity of ≥95%.
[0090] (2) Using the above-mentioned highly pure natural β2-microglobulin, an antigen affinity purification column is prepared.
[0091] (3) Goats were immunized with β2-microglobulin multiple times, and blood was collected after each immunization. Qualified sera were screened by two-way agar diffusion experiment and purified by antigen affinity purification column to obtain highly active β2-MG polyclonal antibodies.
[0092] The β2-MG prepared by the present invention has low cost, simple operation and high purity, and can be used not only as an effective immunogen for the preparation of β2-MG polyclonal antibodies, but also as a calibration material for detection kits. The antibodies prepared by the present invention have good specificity (high analytical sensitivity), a wide linear range and a low detection limit, and have potential and wide application value in clinical diagnosis and in vitro diagnosis.
[0093] The above disclosure is only a preferred embodiment of the method for preparing β2-microglobulin and its polyclonal antibody of the present invention. Of course, it cannot be used to limit the scope of the rights of the present invention. Ordinary technicians in this field can understand that all or part of the processes of the above embodiments and equivalent changes made according to the claims of the present invention are still within the scope of the invention.
Claims
1. A method for preparing β2-microglobulin and its polyclonal antibody, It is characterized in that The following steps are involved: β2-microglobulin solution was extracted from urine after pretreatment; Using the β2-microglobulin as an immunogen to immunize goats multiple times, and collecting serum for qualified testing to obtain qualified serum; The β2-microglobulin is coupled with 4% highly cross-linked agarose pre-activated by N-hydroxysuccinimide to obtain an antigen affinity purification column; High-purity β2-MG polyclonal antibodies are prepared based on the qualified serum and the antigen affinity purification column.
2. The method for preparing β2-microglobulin and its polyclonal antibody according to claim 1, It is characterized in that In "Pretreatment of urine for extraction of β2-microglobulin", include: The urine is filtered, concentrated and dialyzed to obtain a protein solution A; The protein solution A is added to the equilibrium column, and then eluted, collected and concentrated to obtain β2-MG; Treating and testing the β2-MG to obtain protein solution B; Putting the protein solution B into a dialysis bag for dialysis to obtain protein solution C; The protein solution C is subjected to washing, elution and detection to obtain a β2-microglobulin solution.
3. The method for preparing β2-microglobulin and its polyclonal antibody according to claim 1, It is characterized in that In "using the β2-microglobulin as an immunogen to immunize goats multiple times, and collecting serum for qualified testing to obtain qualified serum", the qualified serum is the serum screened by the two-way agar diffusion experiment.
4. The method for preparing β2-microglobulin and its polyclonal antibody according to claim 1, It is characterized in that In "coupling the β2-microglobulin with 4% highly cross-linked agarose pre-activated by N-hydroxysuccinimide to obtain an antigen affinity purification column", the method comprises: The 4% highly cross-linked agarose pre-activated with N-hydroxysuccinimide was washed and diluted to obtain a diluted filler; dialyzing the β2-microglobulin to obtain an antigen solution; Mixing the diluted filler and the antigen solution to obtain a mixed solution A; The mixed solution A is washed to obtain an antigen affinity purification column.
5. The method for preparing β2-microglobulin and its polyclonal antibody according to claim 4, It is characterized in that In "preparing high-purity β2-MG polyclonal antibodies based on the qualified serum and the antigen affinity purification column", it includes: Centrifuging, filtering and mixing the qualified serum to obtain a mixed solution B; Using a buffer to balance the antigen affinity purification column, and loading the mixed solution B, followed by washing and elution to obtain an eluate; To the eluate was added (NH 4 ) 2 SO 4 After stirring, standing and centrifuging, the supernatant is removed, and a buffer solution is added for re-dissolution to obtain a reconstituted solution; The reconstituted solution is dialyzed and centrifuged, and then 0.01-0.5% Proclin300 is added to obtain highly pure β2-MG polyclonal antibodies.
